50 related articles for article (PubMed ID: 16029222)
41. [Cytochrome P450 3A4 and Benzodiazepines].
Otani K
Seishin Shinkeigaku Zasshi; 2003; 105(5):631-42. PubMed ID: 12875231
[TBL] [Abstract][Full Text] [Related]
42. Inhibition and induction of human cytochrome P450 (CYP) enzymes.
Pelkonen O; Mäenpää J; Taavitsainen P; Rautio A; Raunio H
Xenobiotica; 1998 Dec; 28(12):1203-53. PubMed ID: 9890159
[No Abstract] [Full Text] [Related]
43. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians.
Bottorff M; Hansten P
Arch Intern Med; 2000 Aug 14-28; 160(15):2273-80. PubMed ID: 10927723
[No Abstract] [Full Text] [Related]
44. Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.
Coutant DE; Kulanthaivel P; Turner PK; Bell RL; Baldwin J; Wijayawardana SR; Pitou C; Hall SD
Clin Pharmacol Ther; 2015 Jul; 98(1):76-86. PubMed ID: 25808023
[TBL] [Abstract][Full Text] [Related]
45. Lymphocyte activation in allergic reactions elicited by small-molecular-weight compounds.
Merk HF; Baron J; Hertl M; Niederau D; Rübben A
Int Arch Allergy Immunol; 1997; 113(1-3):173-6. PubMed ID: 9130514
[TBL] [Abstract][Full Text] [Related]
46. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro.
Mc Donnell CG; Shorten G; Van Pelt FN
Anaesthesia; 2005 Aug; 60(8):747-53. PubMed ID: 16029222
[TBL] [Abstract][Full Text] [Related]
47. New insights into the pharmacodynamic and pharmacokinetic properties of statins.
Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F
Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838
[TBL] [Abstract][Full Text] [Related]
48. Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence.
Poulsen TS; Vinholt P; Mickley H; Korsholm L; Kristensen SR; Damkier P
Basic Clin Pharmacol Toxicol; 2005 Feb; 96(2):103-10. PubMed ID: 15679472
[TBL] [Abstract][Full Text] [Related]
49. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
Neuvonen PJ
Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
[TBL] [Abstract][Full Text] [Related]
50. Pharmacological interactions of statins.
Paoletti R; Corsini A; Bellosta S
Atheroscler Suppl; 2002 May; 3(1):35-40. PubMed ID: 12044584
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
